Wahl R L, Liebert M, Wilson B S
Cancer Drug Deliv. 1986 Fall;3(4):243-9. doi: 10.1089/cdd.1986.3.243.
The impact of antibody protein dose on tumor accumulation of radiolabeled monoclonal antibody was studied in nude mice with xenografts of human melanomas. 225.28S, a murine monoclonal antibody reactive with a high-molecular weight antigen of melanoma, was radiolabeled with I-125 and administered intraperitoneally to nude mice with human melanoma xenografts. Three days later, the animals were sacrificed, and tumor and normal tissue uptake of I-125 antibody was determined. At doses of 6.25, 62.5, 625 and 1875 ug of monoclonal antibody, there were no significant differences in percent of injected dose reaching the tumor/g of tumor or in the non-tumor uptakes achieved. These findings indicate that in the melanoma system, antibody dose is not a critical determinant of tumor uptake, and additionally indicate that low doses of antibody protein are appropriate for studies involving radioiodinated antibody localization.
在患有人类黑色素瘤异种移植瘤的裸鼠中，研究了抗体蛋白剂量对放射性标记单克隆抗体肿瘤蓄积的影响。225.28S是一种与黑色素瘤高分子量抗原反应的鼠单克隆抗体，用I-125进行放射性标记，并腹腔注射给患有人类黑色素瘤异种移植瘤的裸鼠。三天后，处死动物，测定肿瘤和正常组织对I-125抗体的摄取。在单克隆抗体剂量为6.25、62.5、625和1875微克时，到达肿瘤/克肿瘤的注射剂量百分比或非肿瘤摄取量均无显著差异。这些发现表明，在黑色素瘤系统中，抗体剂量不是肿瘤摄取的关键决定因素，此外还表明低剂量的抗体蛋白适用于涉及放射性碘标记抗体定位的研究。
